Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: Cost minimisation analysis based on a comprehensively tested cohort

BMC Family Practice

Volumn 12, Issue , 2011, Pages

  Arnold, David T ^a   Bentham, Louise M ^b   Jacob, Ruth P ^c   Lilford, Richard J ^b   Girling, Alan J ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COST CONTROL; ECONOMICS; FEMALE; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FUNCTION TEST; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PRIMARY HEALTH CARE; REPRODUCIBILITY;

ADULT; AGED; ALANINE TRANSAMINASE; COHORT STUDIES; COST SAVINGS; FEMALE; HEALTH CARE COSTS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; REPRODUCIBILITY OF RESULTS;

EID: 79952101432     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-12-9     Document Type: Article

References (53)

1. Evaluation of abnormal liver function tests. JK Limdi GM Hyde, Postgrad Med J 2003 79 932 307 312 10.1136/pmj.79.932.307 12840117 (Pubitemid 36819456)
2. Evaluating asymptomatic patients with abnormal liver function test results. RM Theal K Scott, Am Fam Physician 1996 53 6 2111 2119 8623723 (Pubitemid 26135738)
3. Liver enzyme alteration: a guide for clinicians. EG Giannini R Testa V Savarino, CMAJ 2005 172 3 367 379 15684121 (Pubitemid 40208726)
4. Evaluation of abnormal liver-enzyme results in asymptomatic patients. DS Pratt MM Kaplan, N Engl J Med 2000 342 17 1266 1271 10.1056/NEJM200004273421707 10781624 (Pubitemid 30235957)
5. Investigating mildly abnormal serum aminotransferase values. JF Cobbold QM Anstee HC Thomas, BMJ 341 4039 10.1136/bmj.c4039 20675393
6. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. P Sherwood I Lyburn S Brown S Ryder, BMJ 2001 322 276 278 10.1136/bmj.322.7281.276 11157530 (Pubitemid 32178555)
7. Hepatitis C virus infection: the new global epidemic. AA Butt, Expert Rev Anti Infect Ther 2005 3 2 241 249 10.1586/14787210.3.2.241 15918781 (Pubitemid 40598003)
8. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. D Lavanchy, J Viral Hepat 2004 11 2 97 107 10.1046/j.1365-2893.2003.00487.x 14996343 (Pubitemid 38365759)
9. Hepatitis C virus infection in Western Europe. C Trepo P Pradat, J Hepatol 1999 31 Suppl 1 80 83 10.1016/S0168-8278(99)80379-1 10622565 (Pubitemid 30002696)
10. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. B Weber N Van der Taelem-Brule A Berger F Simon M Geudin J Ritter, J Virol Methods 2006 135 1 109 117 10.1016/j.jviromet. 2006.02.009 16567005 (Pubitemid 43744433)
11. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. E Tanaka C Ohue K Aoyagi K Yamaguchi S Yagi K Kiyosawa HJ Alter, Hepatology 2000 32 2 388 3893 10.1053/jhep.2000.9112 10915747
12. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. F Kanwal M Farid P Martin G Chen IM Gralnek GS Dulai BM Spiegel, Am J Gastroenterol 2006 101 9 2076 2089 10.1111/j.1572-0241.2006.00769.x 16968510 (Pubitemid 44337634)
13. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. J Thompson Coon G Rogers P Hewson D Wright R Anderson M Cramp S Jackson S Ryder A Price K Stein, Health Technol Assess 2007 11 34 1 206 17767898
14. BALLETS Study. http://www.hta.ac.uk/protocols/200300380001.pdf
15. M Weinstein H Fineberg, Clinical Decision Analysis Philadelphia: W. B. Saunders Co 1980
16. Test validity of periodic liver function tests in a population of Japanese male bank employees. E Yano K Tagawa K Yamaoka M Mori, J Clin Epidemiol 2001 54 9 945 951 10.1016/S0895-4356(01)00355-9 11520655 (Pubitemid 32755785)
17. Predicting the prevalence of antibody to hepatitis C virus (HCV) in a community by the prevalence of elevated levels of alanine aminotransferase: a method to identify areas endemic for HCV. SN Lu JH Wang YK Kuo HL Kuo TM Chen HD Tung CM Lee SC Chen, Am J Trop Med Hyg 2002 67 2 145 150 12389938
18. Using the prevalence of an elevated serum alanine aminotransferase level for identifying communities with a high prevalence of hepatitis C virus infection. CS Wang ST Wang P Chou, Arch Intern Med 2001 161 3 392 394 10.1001/archinte.161.3.392 11176765 (Pubitemid 32116555)
19. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. R Jamali M Khonsari S Merat M Khoshnia E Jafari A Bahram Kalhori H Abolghasemi S Amini M Maghsoudlu MR Deyhim H Rezvan A Pourshams, World J Gastroenterol 2008 14 18 2867 2871 10.3748/wjg.14.2867 18473412
20. Diagnosis and treatment of chronic hepatitis B. R D'Souza GR Foster, J R Soc Med 2004 97 7 318 321 15229255 (Pubitemid 38918208)
21. Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. IK Veldhuijzen M Toy SJ Hahné GA De Wit SW Schalm RA De Man JH Richardus, Gastroenterology 2009 138 2 522 530 10.1053/j.gastro.2009.10.039 19879275
22. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. M Persico E Persico R Suozzo S Conte M De Seta L Coppola B Palmentieri FC Sasso R Torella, Gastroenterology 2000 118 4 760 764 10.1016/S0016-5085(00)70145-4 10734027 (Pubitemid 30171625)
23. World Health Organization, Geneva, Introduction of hepatitis B vaccine into childhood immunization services Geneva: Department of Vaccines and Biologicals 2001
24. World Health Organization, Internation Travel and Health. Situation as on 1 January 2005 Geneva: Marketing and Dissemination, World Health Organization 2005
25. World Health Organization, International Travel and Health. Situation as on 1 January 2010 Geneva: WHO Press 2010
26. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. DW Hutton D Tan SK So ML Brandeau, Ann Intern Med 2007 147 7 460 469 17909207 (Pubitemid 351664518)
27. Two-sided confidence intervals for the single proportion: comparison of seven methods. RG Newcombe, Stat Med 1998 17 8 857 872 10.1002/(SICI)1097- 0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E 9595616 (Pubitemid 28185165)
28. Precis of Simple heuristics that make us smart. PM Todd G Gigerenzer, Behav Brain Sci 2000 23 5 727 741 discussion 742-780 10.1017/S0140525X00003447 11301545
29. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. DR Dufour JA Lott FS Nolte DR Gretch RS Koff LB Seeff, Clin Chem 2000 46 12 2050 2068 11106350
30. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. HC Kim CM Nam SH Jee KH Han DK Oh I Suh, BMJ 2004 328 7446 983 10.1136/bmj.38050.593634.63 15028636
31. Health outcomes following liver function testing in primary care: a retrospective cohort study. DJ McLernon PT Donnan S Ryder P Roderick FM Sullivan W Rosenberg JF Dillon, Fam Pract 2009 26 4 251 259 10.1093/fampra/cmp025 19439435
32. Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). PT Donnan D McLernon JF Dillon S Ryder P Roderick F Sullivan W Rosenberg, Health Technol Assess 2009 13 25 ii iv ix-xi,1-134
33. Is severe liver disease a common outcome for people with chronic hepatitis C? GJ Dore AJ Freeman M Law JM Kaldor, J Gastroenterol Hepatol 2002 17 4 423 430 10.1046/j.1440-1746.2002.02730.x 11982723 (Pubitemid 34534080)
34. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. S Bellentani C Tiribelli G Saccoccio M Sodde N Fratti C De Martin G Cristianini, Hepatology 1994 20 6 1442 1449 10.1002/hep.1840200611 7982643 (Pubitemid 24359054)
35. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. GM Pendino A Mariano P Surace CA Caserta MT Fiorillo A Amante S Bruno C Mangano I Polito F Amato R Cotichini T Stroffolini A Mele ACE Collaborating Group, Hepatology 2005 41 5 1151 1159 10.1002/hep.20689 15841464 (Pubitemid 40593924)
36. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. S Daniel T Ben-Menachem G Vasudevan CK Ma M Blumenkehl, Am J Gastroenterol 1999 94 10 3010 3014 10.1111/j.1572-0241.1999.01451.x 10520861 (Pubitemid 29482774)
37. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. UL Mathiesen LE Franzen A Fryden U Foberg G Bodemar, Scand J Gastroenterol 1999 34 1 85 91 10.1080/ 00365529950172880 10048738 (Pubitemid 29074792)
38. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. R Hultcrantz H Glaumann G Lindberg LH Nilsson, Scand J Gastroenterol 1986 21 1 109 113 10.3109/00365528609034632 3952445 (Pubitemid 16177472)
39. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. MW Whitehead ND Hawkes I Hainsworth JG Kingham, Gut 1999 45 1 129 133 10.1136/gut.45.1.129 10369716 (Pubitemid 29301857)
40. Prevention of Hepatitis B with the Hepatitis B vaccine. GA Poland RM Jacobson, NEJM 2004 351 2832 2838 10.1056/NEJMcp041507 15625334 (Pubitemid 40051907)
41. Changing illness perceptions after myocardial infarction: an early intervention randomized controlled trial. KJ Petrie LD Cameron CJ Ellis D Buick J Weinman, Psychosom Med 2002 64 4 580 586 12140347 (Pubitemid 34791160)
42. A meta-analysis of fear appeals: implications for effective public health campaigns. K Witte M Allen, Health Educ Behav 2000 27 5 591 615 10.1177/109019810002700506 11009129
43. The cost-effectiveness of testing for hepatitis C in former injecting drug users. E Castelnuovo J Thompson-Coon M Pitt M Cramp U Siebert A Price K Stein, Health Technol Assess 2006 10 32 ii iv ix-xii, 1-93 16948891
44. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis. K Stein K Dalziel A Walker B Jenkins A Round P Royle, J Hepatol 2003 39 5 814 825 10.1016/S0168-8278(03)00392-1 14568266 (Pubitemid 37372193)
45. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. J Nakamura K Terajima Y Aoyagi K Akazawa, Tohoku J Exp Med 2008 215 1 33 42 10.1620/tjem.215.33 18509233 (Pubitemid 351791266)
46. Health Protection Agency - Hepatitis C. http://www.hpa.org.uk/Topics/ InfectiousDiseases/InfectionsAZ/HepatitisC/
47. Health Protection Agency - Hepatitis B. http://www.hpa.org.uk/Topics/ InfectiousDiseases/InfectionsAZ/HepatitisB/
48. Haemochromatosis. M Worwood, Clin Lab Haematol 1998 20 2 65 75 10.1046/j.1365-2257.1998.00028.x 9681215 (Pubitemid 28206936)
49. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. JV Metcalf RS Bhopal J Gray D Howel OF James, Int J Epidemiol 1997 26 4 830 836 10.1093/ije/26.4.830 9279616 (Pubitemid 27367860)
50. AutoImmune Hepatitis Support Group. http://www.autoimmunehepatitis.co.uk/
51. Estimate of the frequency of Wilson's disease in the US Caucasian population: a mutation analysis approach. L Olivarez M Caggana KA Pass P Ferguson GJ Brewer, Ann Hum Genet 2001 65 Pt 5 459 463 10.1046/j.1469-1809.2001. 6550459.x 11806854 (Pubitemid 33149890)
52. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. FJ de Serres, Chest 2002 122 5 1818 1829 10.1378/chest.122.5.1818 12426287 (Pubitemid 35366098)
53. [Clinical characteristics of factory workers with asymptomatic liver function test abnormalities found on serial health examination]. KM Kim YJ Kim KH Lee D Paek, Korean J Hepatol 2005 11 2 144 156 15980673